UBS Group AG Purchases 10,706 Shares of Labcorp Holdings Inc. $LH

Key Points

• UBS Group AG increased its Labcorp stake by 10,706 shares in Q4 to 495,535 shares (about 0.60% ownership) valued at $124.32 million.
• Labcorp beat Q1 estimates with EPS $4.25 vs. $4.09 and $3.54B revenue, and raised FY2026 guidance to $17.70–$18.35 EPS and roughly $14.7–$14.8B in revenue, though the stock's intraday reaction was muted.
• The company declared a quarterly dividend of $0.72 ($2.88 annually, ~1.1% yield), while insiders sold about 16,113 shares (~$4.55M) over the last 90 days and institutional investors own ~95.94% of the stock.

UBS Group AG lifted its position in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 495,535 shares of the medical research company's stock after purchasing an additional 10,706 shares during the period. UBS Group AG owned 0.60% of Labcorp worth $124,320,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in LH. Victory Capital Management Inc. lifted its position in shares of Labcorp by 20.0% during the third quarter. Victory Capital Management Inc. now owns 2,637,350 shares of the medical research company's stock valued at $756,878,000 after purchasing an additional 440,224 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Labcorp by 15.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company's stock worth $604,488,000 after buying an additional 289,029 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Labcorp by 79.1% in the 3rd quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company's stock worth $178,996,000 after buying an additional 275,454 shares during the last quarter. Mondrian Investment Partners LTD purchased a new position in shares of Labcorp in the 3rd quarter worth about $75,208,000. Finally, Woodline Partners LP increased its holdings in Labcorp by 598.1% during the third quarter. Woodline Partners LP now owns 287,146 shares of the medical research company's stock worth $82,428,000 after buying an additional 246,014 shares during the last quarter. 95.94% of the stock is owned by institutional investors.

Labcorp Stock Down 0.2%

LH stock opened at $256.37 on Friday. The company has a current ratio of 1.73, a quick ratio of 1.23 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 1-year low of $239.67 and a 1-year high of $293.72. The stock has a market cap of $21.07 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 1.73 and a beta of 1.02. The company's 50 day moving average is $270.69 and its 200 day moving average is $267.48.

Labcorp (NYSE:LH - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.51 billion. During the same quarter last year, the business earned $3.84 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 17.91 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp's payout ratio is presently 27.53%.

Insider Activity at Labcorp

In related news, CEO Adam H. Schechter sold 8,705 shares of the business's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the transaction, the chief executive officer owned 80,773 shares in the company, valued at $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of the business's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the transaction, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. This represents a 4.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 16,113 shares of company stock worth $4,547,450 over the last ninety days. Corporate insiders own 0.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Morgan Stanley restated an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Piper Sandler increased their price target on shares of Labcorp from $270.00 to $300.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Wall Street Zen raised shares of Labcorp from a "hold" rating to a "buy" rating in a report on Saturday. Evercore reissued an "outperform" rating and issued a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Finally, Weiss Ratings raised shares of Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $308.00.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 results beat Street estimates — EPS of $4.25 vs. $4.09 est. and revenue of $3.54B vs. $3.51B, with revenue up ~5.8% year‑over‑year. Management pointed to broad segment growth driving the beat. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Raised FY2026 guidance — EPS guidance range set to $17.70–$18.35 and revenue guidance roughly $14.7B–$14.8B, reflecting steady diagnostics demand that management says supports continued growth. Labcorp raises full-year forecasts on steady diagnostics demand
• Positive Sentiment: Analyst reaction was initially favorable — outlets noted pre‑market gains after the beat and the raised view, signaling positive near‑term sentiment from some desks. LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper review (slides, PR, and call transcript). Useful for investors who want line‑by‑line detail on margins, segment trends and cadence. Labcorp Holdings Inc. 2026 Q1 - Results - Earnings Call Presentation Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Longer‑term valuation context: coverage pieces highlight LH as a value/quality name given its margin profile and ROE, which may attract income/value investors. Here's Why Labcorp Holdings (LH) is a Strong Value Stock
• Negative Sentiment: Market reaction turned muted/negative intraday — reasons include guidance that is only modestly above consensus (company range roughly in line with Street forecasts), possible profit‑taking after the beat, and limited incremental upside in margin guidance. This helps explain why the stock is down despite the beat. Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.